Read more
Informationen zum Autor Matthias Von Herrath is the editor of How Do We Best Employ Animal Models for Type 1 Diabetes and Multiple Sclerosis?, Volume 1103, published by Wiley. Mark Atkinson is a medical researcher best known for his contributions to research seeking to predict, prevent, and cure type 1 diabetes. He is the author of over 425 publications and is one of the world's most cited diabetes researchers. Klappentext Our understanding of the genetics and pathophysiology of animal models for autoimmune diseases such as type 1 diabetes and multiple sclerosis has increased significantly in the past few years. The central themes of this volume are the necessity for novel and improved models, the optimal use of information from animal models to understand pathogenesis of the human disease, and the rational development of novel immunotherapeutics. This volume is intended to foster discussion on the utility of currently available animal models, to suggest methods for improving upon present models, and to advance translational research in these fields. NOTE: Annals volumes are available for sale as individual books or as a journal. For information on institutional journal subscriptions, please visit www.blackwellpublishing.com/nyas . ACADEMY MEMBERS: Please contact the New York Academy of Sciences directly to place your order ( www.nyas.org ). Members of the New York Academy of Science receive full-text access to the Annals online and discounts on print volumes. Please visit www.nyas.org/membership/main.asp for more information about becoming a member. Zusammenfassung Our understanding of the genetics and pathophysiology of animal models for autoimmune diseases such as type 1 diabetes and multiple sclerosis has increased significantly in the past few years. Inhaltsverzeichnis Introduction. Part I: Controversies Surrounding the Use of Animal Models in Type 1 Diabetes and Multiple Sclerosis:. 1. Are Insights Gained from NOD Mice Sufficient to Guide Clinical Translation? Another Inconvenient Truth: Bart O. Roep. 2. Building Different Mouse Models for Human MS: Estelle Bettelli. 3. Autoimmunity and ß Cell Regeneration in Mouse and Human Type 1 Diabetes. The Peace Is Not Enough: Vitaly Ablamunits, Nicole A. Sherry, Jake A. Kushner, and Kevan C. Herold. 4. Diabetes Research in Jeopardy: The Extinction of Clinical Diabetes Researchers: Aldo A. Rossini and Dale L. Greiner. Part II. New Methods of Discovery for Questions of Pathogenesis and Therapy:. In Silico. 5. The Virtual NOD Mouse: Applying Predictive Biosimulation to Research in Type 1 Diabetes: Yanan Zheng, Huub T. C. Kreuwel, Daniel L. Young, Lisl K. M. Shoda, Saroja Ramanujan, Kapil G. Gadkar, Mark A. Atkinson, and Chan C. Whiting. 6. Dosing and Timing Effects of Anti-CD40L Therapy: Predictions from a Mathematical Model of Type 1 Diabetes: Kapil G. Gadkar, Lisl K. M. Shoda, Huub T. C. Kreuwel, Saroja Ramanujan, Yanan Zheng, Chan C. Whiting, and Daniel L. Young. Humanized, Transgenic, or Congenic Models. 7. Autoreactive T Cells in a Partially Humanized Murine Model of T1D: John A. Gebe, Ben Falk, Kellee Unrath, and Gerald T. Nepom. 8. Humanized NOD/LtSz-scid IL2 Receptor Common Gamma Chain Knockout Mice in Diabetes Research: Leonard D. Shultz, Todd Pearson, Marie King, Lisa Giassi, Lisa Carney, Bruce Gott, Bonnie Lyons, Aldo A. Rossini, and Dale L. Greiner. 9. Development of New-Generation HU-PBMC-NOD/SCID Mice to Study Human Islet Alloreactivity: Marie King, Todd Pearson, Leonard D. Shultz, Jean Leif, Rita Bottino, Massimo Trucco, Mark Atkinson, Clive Wasserfall, Kevan Herold, John P. Mordes, Aldo A. Rossini, and Dale L. Greiner. 10. Resistance to the Induction of Mixed Chimerism in ...
